Reasons to Retain IQVIA (IQV) Stock in Your Portfolio Now

IQVIA Holdings IQV stock has gained 7.5%, outperforming 2.5% and 6.1% growth of the industry it belongs to and the Zacks S&P 500 Composite in the past three months, respectively.

IQV has an expected long-term (three to five years) EPS growth rate of 10.2%. The company’s earnings for 2024 and 2025 are anticipated to grow 8.6% and 13% year over year, respectively. Revenues are expected to increase 3.5% in 2024 and 7.9% in 2025.

Factors That Auger Well

IQVIA’s robust capabilities place it strongly in the life sciences space and enable it to make the most of the market opportunities. The company has a strong healthcare-specific global IT infrastructure, a robust real-world solutions ecosystem, analytics-driven clinical development capabilities, and a growing set of proprietary clinical and commercial applications that assist in growing and retaining relationships with healthcare stakeholders. IQV has developed trusted relationships using its combined offerings of research and development, and commercial services, resulting in a diversified base of more than 10,000 clients (approximately 400 net new clients in 2023) in above 100 nations.

IQVIA Holdings Inc. Revenue (TTM)


IQVIA Holdings Inc. Revenue (TTM)

IQVIA Holdings Inc. revenue-ttm | IQVIA Holdings Inc. Quote

IQVIA’s addressable market size is more than $330 billion and consists of outsourced research and development, technology-enabled clinical, real-world evidence, and connected health and commercial operations markets. The company is expanding its R&D site network and management organization via strategic acquisitions that offer clinical research coordination study feasibility and patient recruitment capability. Lab business capabilities expanded through launching a synthetic antibody discovery offering. Also, IQVIA has expanded its partnership with major pharma firms, securing six new global oncology trials.

In 2023, 2022 and 2021, the company repurchased shares worth $992 million, $1.17 billion and $406 million, respectively. Such strategies not only instill investors’ confidence but also positively impact the bottom line.

Some Risks

IQVIA’s current ratio at the end of fourth-quarter 2023 was pegged at 0.86, lower than the year-ago quarter's 0.89. A current ratio of less than 1 often indicates that the company may have problems paying off its short-term obligations.

The global presence of IQV makes it vulnerable to foreign currency exchange rate fluctuations risks. In 2023, 30% of its total revenues were generated in 60 different currencies outside the United States.

Zacks Rank & Stocks to Consider

IQVIA currently carries a Zacks Rank #3 (Hold).

A couple of better-ranked stocks from the broader Zacks Business Services sector are Waste Connection WCN and Viad Corp VVI.

Waste Connection currently has a Zacks Rank of 2 (Buy). It has a long-term earnings growth expectation of 12.6%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

WCN delivered a trailing four-quarter earnings surprise of 1.9%, on average.

Viad Corp presently carries a Zacks Rank of 2. It has a long-term earnings growth expectation of 15%.

VVI delivered a trailing four-quarter earnings surprise of 8%, on average.

Free Report – The Bitcoin Profit Phenomenon

Zacks Investment Research has released a Special Report to help you pursue massive profits from the world’s first and largest decentralized form of money.

No guarantees for the future, but in the past three presidential election years, Bitcoin’s returns were as follows: 2012 +272.4%, 2016 +161.1%, and 2020 +302.8%.

Zacks predicts another significant surge. Click below for Bitcoin: A Tumultuous Yet Resilient History.

Download Now – Today It’s FREE >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Waste Connections, Inc. (WCN) : Free Stock Analysis Report

Viad Corp (VVI) : Free Stock Analysis Report

IQVIA Holdings Inc. (IQV) : Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.